For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
A multi-strain meningococcal B vaccine finally arrives in New Zealand
+Print Archive
PRACTICE
A multi-strain meningococcal B vaccine finally arrives in New Zealand
Wednesday 24 October 2018, 12:30 AM

Bexsero has been on the UK childhood schedule since September 2015
CHILD HEALTH
The availability of a meningococcal B vaccine is good news for New Zealand, as MenB is the most prevalent group and the burden of invasive meningococcal disease is high. The overseas experience is summarised here, as well as the recommendations for its use in New Zealand
Key points
-Group B meningococcal (MenB) disease is the most common type of invasive meningococcal disease in New Zealand, with the highest incide
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.